Travaux scientifiques

Prof. Dr. İrfan Çiçin

318 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil
  1. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak

    Turkish Journal of Surgery, 2020

    DOI 10.5578/turkjsurg.4815 PMID 33015560 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  2. Clinicopathological and prognostic characteristics of acral metastases in patients with malignant disease: A retrospective study

    Acta Orthopaedica et Traumatologica Turcica, 2020

    DOI 10.5152/j.aott.2020.20052 PMID 33650515 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  3. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.

    PubMed, 2020

    PMID 32862574 6 citations (Europe PMC) Source : OpenAlex

  4. Relationship between the Size and Location of the Mass and Hilar and Mediastinal Lymph Node Metastasis in Early and Locally Advanced Non-small Cell Lung Cancer

    Journal of College of Physicians And Surgeons Pakistan, 2020

    DOI 10.29271/jcpsp.2020.02.172 PMID 32036826 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  5. The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas

    Polish Journal of Radiology, 2020

    DOI 10.5114/pjr.2020.95945 PMID 32612724 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  6. Prognostic Effect of Albumin-Bilirubin Grade on Survival in Advance Gastric Cancer Patients with de-novo Liver Metastasis

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-77649 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  7. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study

    International Journal of Clinical Oncology, 2020

    DOI 10.1007/s10147-020-01729-3 PMID 32591963 3 citations (Europe PMC) Source : OpenAlex

  8. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.

    PubMed, 2020

    PMID 33099930 5 citations (Europe PMC) Source : OpenAlex

  9. Targeted next-generation sequencing as a diagnostic tool in gastrointestinal system cancer/polyposis patients

    Tumori Journal, 2020

    DOI 10.1177/0300891620919171 PMID 32390558 2 citations (Europe PMC) Source : OpenAlex

  10. Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-75080 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  11. Stage I colon cancer that spreads into a colovesical fistula-mediated bladder due to crohn's disease: A case report

    Current Problems in Cancer Case Reports, 2020

    DOI 10.1016/j.cpccr.2020.100010 Texte intégral en libre accèsSource : OpenAlex

  12. Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.tps1107 Source : OpenAlex

  13. Pandemi Döneminde Kanser Klinik Araştırmaları

    Türkiye Klinikleri COVID - 19, 2020

    Source : OpenAlex

  14. Gastrointestinal Tümörlerde Nütrisyonel Tedavi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2020

    Source : OpenAlex

  15. Optimal Cytoreduction is an Independent Prognostic Factor in Ovarian Carcinosarcoma: A Turkish Gynecologic Oncology Group Study

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2019-73073 Texte intégral en libre accèsSource : OpenAlex

  16. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155220963535 PMID 33050804 Source : OpenAlex

  17. Comparison of Neoadjuvant Chemotherapy and Bladder-Preserving Chemoradiation in Patients with Non-Metastatic, Muscle-Invasive Bladder Cancer: A Single-Center Experience

    Journal of Oncological Sciences, 2020

    DOI 10.37047/jos.2020-77532 Texte intégral en libre accèsSource : OpenAlex

  18. Yaşlı Kanser Hastalarında İmmünoterapi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2020

    Source : OpenAlex

  19. Multicenter real life expeMulticenter real life experience of biological agents in patients with metastatic colorectal cancerrience of biological agents in patients with metastatic colorectal cancer

    2020

    Source : OpenAlex

  20. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

    Bursa Uludag University - AVESIS, 2020

    Source : OpenAlex

  21. PROGNOSTIC AND PREDICTIVE MARKERSOF FOLFIRI/AFLIBERCEPT IN PATIENTS WITHMETASTATIC COLORECTAL CANCER (TOG STUDY)Cihan Erol1, Mutlu Hızal2, Irem Bilgetekin3, Sinem Akbas4,Duygu Bayir Garbioglu5, Jamshid Hamdard6, Cagatay Arslan7,Alper Sevinc8, Ahmet Kucukarda9, Dilek Gurgenyatagi10, EmreCakir11, Aykut Demirkiran12, Murat Araz12, Sercan On13, IzzetDogan14, Atike Pinar Erdogan15, Sinan Koca16, Pinar Kubilay17,Onder Eren18, Deniz Tataroglu Ozyukseler19, Mahmut EmreYildirim19, Ebru Cilbir20, Emir Celik21, Aykut Bahceci22, HalilTaskaynatan23, Abdulkerim Oyman24, Gulhan Ipek Deniz25,Serkan Menenekse26, Engin Kut26, Ahmet Gulmez27, AbdullahSakin28, Erdinc Nayir29, Ramazan Acar30, Seda Kahraman1,Erdem Sen31, Ali Inal32, Serdar Turhal33, Ali Osman Kaya34, SemraPaydas35, Didem Tastekin14, Ilhan Hacıbekiroglu11, Irfan Cicin9,Ahmet Bilici6, Didem Sener Dede1, Muhammed Bulent Akinci1,Nil Molinas Mandel36, Berna Oksuzoglu3, Dogan Uncu2, BulentYalcin1, Mehmet Artac12, Mehmet Ali Nahit Sendur1

    AYBU AVESIS, 2020

    Source : OpenAlex

  22. IMMUNOTHERAPY IN ELDERLY CANCER PATIENTS

    Turkiye Klinikleri eBooks, 2020

    DOI 10.5336/978-625-401-191-7_p106 Source : OpenAlex

  23. Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

    Trakya University's Institutional Open Access System (Trakya University), 2020

    Source : OpenAlex

  24. Evaluating sun protection behaviors and skin self‐examination practices among the family members of melanoma patients in Turkey: A cross‐sectional survey study

    Dermatologic Therapy, 2020

    DOI 10.1111/dth.14268 PMID 32882080 6 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  25. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

    Annals of Oncology, 2019

    DOI 10.1093/annonc/mdz061 PMID 30796821 87 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

    The Lancet Oncology, 2019

    DOI 10.1016/s1470-2045(19)30668-0 PMID 31753727 70 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  27. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.19.01348 PMID 31751163 79 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  28. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

    Journal of Oncology Pharmacy Practice, 2019

    DOI 10.1177/1078155219883004 PMID 31653193 17 citations (Europe PMC) Source : OpenAlex

  29. Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases

    Bosnian Journal of Basic Medical Sciences, 2019

    DOI 10.17305/bjbms.2019.4474 PMID 31999935 21 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  30. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

    Clinical Colorectal Cancer, 2019

    DOI 10.1016/j.clcc.2019.05.003 PMID 31221542 14 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  31. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer

    Cancer Chemotherapy and Pharmacology, 2019

    DOI 10.1007/s00280-019-03779-5 PMID 30680522 8 citations (Europe PMC) Source : OpenAlex

  32. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102.

    PubMed, 2019

    PMID 31786894 7 citations (Europe PMC) Source : OpenAlex

  33. Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases

    Archives of Gynecology and Obstetrics, 2019

    DOI 10.1007/s00404-019-05160-6 PMID 30982145 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  34. Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?

    PubMed, 2019

    PMID 31256595 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  35. The albumin-bilirubin (ALBI) grade as a significant prognostic factor in colorectal cancer patients with liver metastases

    Journal of Surgery and Medicine, 2019

    DOI 10.28982/josam.597751 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  36. Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.15_suppl.4088 23 citations (OpenAlex) Source : OpenAlex

  37. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.15_suppl.4037 8 citations (OpenAlex) Source : OpenAlex

  38. Pregnancy and Gastrointestinal Cancers

    Springer eBooks, 2019

    DOI 10.1007/978-3-030-18890-0_36 Source : OpenAlex

  39. Effect of clinical and pathological features of gastrointestinal stromal tumors on overall survival and prognosis: Single center experience

    Journal of Oncological Sciences, 2019

    DOI 10.1016/j.jons.2019.10.003 Texte intégral en libre accèsSource : OpenAlex

  40. Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

    Springer eBooks, 2019

    DOI 10.1007/978-3-030-16792-9_42 Source : OpenAlex

  41. GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTİ- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ

    AYBU AVESIS, 2019

    Source : OpenAlex

  42. GERIATRIK (≥75 YAS), KASTRASYON DIRENCLI METASTATIK PROSTAT KANSERI (KDMPK) HASTALARINDA 1. BASAMAK ANTI- ANDROJEN TEDAVI SONUCLARI- GERCEK YASAM VERISI

    AYBU AVESIS, 2019

    Source : OpenAlex

  43. Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçları- Gerçek Yaşam Verisi

    AYBU AVESIS, 2019

    Source : OpenAlex

  44. Kastrasyon Direncli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yas) Hastalarda 1. Basamak Dosetaksel Tedavi Sonucları- Gercek Yasam Verisi

    AYBU AVESIS, 2019

    Source : OpenAlex

  45. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

    Cancer Chemotherapy and Pharmacology, 2018

    DOI 10.1007/s00280-018-3713-6 PMID 30374523 13 citations (Europe PMC) Source : OpenAlex

  46. Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experince from Turkey

    Van Yüzüncü Yıl University Academic Data Management System, 2018

    Source : OpenAlex

  47. Crizotinib Efficacy in ALK-positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey

    Bursa Uludag University - AVESIS, 2018

    Source : OpenAlex

  48. CRIZOTINIB EFFICACY IN ALK-POSITIVE ADVANCEDSTAGE NON-SMALL CELL LUNG CANCER PATIENTS: A REAL-WORLD EXPERIENCE FROM TURKEY

    Kocaeli Üniversitesi - AVESİS, 2018

    Source : OpenAlex

  49. Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA)

    Clinical and Applied Thrombosis/Hemostasis, 2018

    DOI 10.1177/1076029617753538 PMID 29455568 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  50. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    New England Journal of Medicine, 2018

    DOI 10.1056/nejmoa1717002 PMID 29972759 1 891 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex